Blue Water Ventures International Acquires Psycheceutical, Inc.
January 20, 2022
Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.
- Buyers
- Blue Water Ventures International, Inc.
- Targets
- Psycheceutical, Inc.
- Industry
- Biotechnology
- Location
- Florida, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Cybin Inc. Acquires Small Pharma Inc.
August 28, 2023
Biotechnology
Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.
-
Voxtur Acquires Blue Water Financial Technologies
August 12, 2022
Financial Services
Voxtur Analytics Corp.'s U.S. subsidiary executed an agreement to acquire all membership interests of Blue Water Financial Technologies Holding Company, LLC, a SaaS-based mortgage asset valuation and MSR trading platform. The transaction is valued at approximately USD $101 million (USD $30M cash plus share consideration), is expected to be accretive, and is subject to regulatory approvals and customary closing conditions.
-
PhaseWell Research Acquires Bio Behavioral Health
January 21, 2026
Healthcare Services
PhaseWell Research, a national clinical research site company, announced that Bio Behavioral Health has joined its network to expand access to neuropsychiatric and CNS clinical trials. The deal strengthens PhaseWell's community-based research capabilities and broadens patient access to complex clinical studies across its growing national footprint.
-
Beckley Psytech Acquires Eleusis Therapeutics Limited
October 24, 2022
Biotechnology
Beckley Psytech Limited has acquired 100% of Eleusis Therapeutics Limited in an all-equity transaction, adding Eleusis' clinical-stage assets (including ELE-101) and its R&D team to Beckley's pipeline. Eleusis CEO Shlomi Raz will join Beckley as Chief Business Officer as the companies integrate to accelerate development of short-duration psychedelic therapies.
-
Lucy Scientific Discovery Acquires BlueSky Wellness
September 12, 2023
Consumer Products
Lucy Scientific Discovery Inc. (NASDAQ: LSDI) agreed to acquire BlueSky Wellness Inc. in an all-stock transaction that will add a portfolio of plant-based wellness CPG brands (Keoni, Keoni Sport, Blush Wellness, AMMA Healing) and e-commerce capabilities. BlueSky shareholders will receive 3.5 million Lucy shares plus up-to-five-year EBITDA-based earnouts; Lucy expects the combined transactions with its High Times IP acquisition to add at least $30 million in revenue and $10 million of EBITDA in the first 12 months.
-
Beckley Waves (via NueCo Holdings PBC) Acquires Nue Life Health
October 26, 2023
Healthcare Services
Beckley Waves, a venture studio focused on building companies in the psychedelic ecosystem, has acquired the assets of Nue Life Health Inc. through a newly launched portfolio company, NueCo Holdings PBC. The acquisition will allow Beckley Waves to scale Nue Life's at-home ketamine-assisted therapy platform and expand access to underserved patients across the United States.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.